Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin [bevacizumab] Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 27 Sep 2018 Planned End Date changed from 1 Feb 2019 to 1 Aug 2019.
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.